
GC Therapeutics programs patient-derived stem cells into any cell type using synthetic biology for various applications.
Founded with technology developed in Professor George Church's lab at Harvard Medical School, GC Therapeutics is a synthetic biology company focused on programming patient-derived stem cells into any cell type efficiently and scalably. Their core mission is to revolutionize cell therapy by creating customizable SuperCells™ for various medical applications. The company aims to streamline the process of dictating cell fates in a single step, thereby accelerating the development of personalized treatments.
Notable affiliated individuals include Professor George Church, a pioneer in synthetic biology. GC Therapeutics has achieved significant milestones in verifying cells for multiple applications, demonstrating the potential of their technology in real-world scenarios. Their innovative approach has positioned them as a key player in the synthetic biology market, promising substantial impact on the future of personalized medicine and cell therapy.

Satellite Bio
satellite.bio

Garuda Therapeutics
garudatx.com

Think Bioscience

Modulari-T
modularit.bio

Axent Biosciences
axentbio.com
Green Cross Lab Cell

Synlife
synlifebio.com

Slingshot Biosciences
slingshotbio.com

GentiBio
gentibio.com

RootPath Genomics
rootpath.com

Regel Therapeutics

Jupiter Therapeutics
jupitertx.com

Cellino
cellinobio.com

Stemson Therapeutics
stemsontx.com

Stemgenics
stemgenics.com

Stellate DNA
stellatedna.com

Strm.Bio
strm.bio

Kyverna Therapeutics
kyvernatx.com

Hepatx
hepatx.com

Senti Biosciences
sentibio.com
GC Therapeutics' most recent funding round was for $339.9k (USD) in October 2023.
As of Oct 12, 2023, GC Therapeutics has disclosed funding of $339.9k (USD).